Herpes zoster vaccination and new diagnoses of dementia: A quasi-randomized study in Australia

ImportanceTaking advantage of a natural experiment in Wales, our group has recently provided evidence that herpes zoster (HZ) vaccination appears to prevent or delay dementia. Exploiting a similar natural experiment in Australia, this present study investigated the effect of HZ vaccination on dementia occurrence in a different population and health system setting. ObjectiveTo determine the effect of HZ vaccination on the probability of receiving a new diagnosis of dementia in the future. Design, Setting, and ParticipantsIn Australia, starting on November 1 2016, live-attenuated HZ vaccination was provided for free to individuals aged 70 to 79 years of age through primary care providers. Thus, those whose 80th birthday was just a few weeks prior to November 1 2016 never became eligible, whereas those whose 80th birthday was just a few weeks later were eligible. The key strength of our approach is that one would not expect that these comparison groups who differ in their age by only a minute degree would, on average, differ in any of their health characteristics and behaviors. We analyzed primary healthcare records with week-of-birth information from 65 general practices across Australia using regression discontinuity. ExposureEligibility for HZ vaccination based on ones date of birth. Main outcomeNew diagnoses of dementia as recorded in primary care electronic health record data. ResultsAs expected, in our sample of 101,219 patients, individuals born just before versus shortly after the date-of-birth eligibility threshold (November 2 1936) for HZ vaccination were well-balanced in their past preventive health services uptake and chronic disease diagnoses. There was an abrupt increase of 16.4 (95% CI: [13.2 - 19.5], p < 0.001) percentage points in the probability of ever receiving HZ vaccination between patients born shortly before versus shortly after the date-of-birth eligibility threshold. The eligibility rules of the HZ vaccination program, thus, created comparison groups just on either side of the date-of-birth eligibility threshold who were likely similar to each other, except for a large difference in their probability of receiving the intervention (HZ vaccination) of interest. Drawing on a sample of 18,402 patients, we find that eligibility for HZ vaccination (i.e., being born shortly after versus shortly before November 2 1936) decreased the probability of receiving a new dementia diagnosis over 7.4 years by 1.8 percentage points (95% CI: [0.4 - 3.3], p = 0.013). Being eligible for HZ vaccination did not affect the probability of taking up other preventive health services (including other vaccinations), nor the probability of being diagnosed with other common chronic conditions than dementia. Conclusions and RelevanceCorroborating our quasi-experimental findings from Wales in a different population, this study provides important evidence on the potential benefits of HZ vaccination for dementia because its quasi-experimental design allows for conclusions that are more likely to be causal than those of more commonly conducted associational studies. Key pointsO_ST_ABSQuestionC_ST_ABSWhat is the effect of herpes zoster vaccination on the probability of receiving a new diagnosis of dementia in the future? FindingsIn this quasi-experimental study of electronic health record data from Australia, being eligible for herpes zoster vaccination based solely on ones date of birth significantly decreased the probability of receiving a new dementia diagnosis over 7.4 years by 1.8 percentage points. Meaning: Due to its quasi-experimental design, this study provides evidence for a beneficial effect of herpes zoster vaccination for preventing or delaying dementia that is more likely to be causal than the associations reported in the existing correlational evidence.